Several studies have demonstrated that CDK4/6 inhibitors can enhance antitumor immunity by promoting interferon production, improving tumor antigen presentation, suppressing regulatory T cell proliferation, and increasing tumor infiltration and the activation of effector T cells, thus potentially enhancing the response to ICIs (Figure 2) [64,65]. The gene discussed is CDK4; the disease is neoplasm.